Pharmacovigilance is Not Just About Compliance
Add bookmark
Dr. Viraj Suvarna, Medical Director and Head of Medical Affairs at Boehringer Ingelheim, joins Andrea Charles from Pharma IQ to discuss the importance of training and re-training field operatives to report adverse drug events (ADEs) and how understanding the risk-benefit profile of your product can maximise benefit and minimising risk, by making sure the right drug, goes to the right patient, at the right time.
[inlinead]
Tags:
Viraj Survarna
Boehringer Ingelheim
robust pharmacovigilance systems
pharmacovigilance
Pharmacovigilance India
ADE
ADR
adverse drug events
adverse drug reactions
risk-benefit profiles
pharmacointelligence system
pharmacodiligence
AIR
Clearing the AIR workshops
benefit-risk ratio
